导读 近日，工业和信息化部公示2025年度中国消费名品名单，我省的九芝堂、圣得西、安化黑茶、湘潭湘莲、南县稻虾米、千金共6 个品牌拟入选。具体公示内容和名单如下： 工业和信息化部2025年度中国消费名品名单公示 根据《工业和信息化部办公厅关于组织征集2025年度中国消费名品的通知》（工信厅消费函〔2025〕378号），经企业申报、省 级工业和信息化主管部门初审推荐、专家评审，并征求国家发展改革委、民政部、生态环境部、商务部、应急管理部、市场监 管总局、国家知识产权局、国家药监局、全国妇联、中国残联、全国工商联、中国消费者协会等单位及有关行业协会意见，现 将2025年度中国消费名品名单公示5个工作日。如有异议，请在公示期内与工业和信息化部消费品工业司联系。 公示时间：2026年1月5日至2026年1月9日 附件：2025年度中国消费名品名单 工业和信息化部消费品工业司 2026年1月4日 2 | 41 | 泉阳泉 | 吉林森工集团泉阳泉饮品有限公司 | | --- | --- | --- | | 42 | 哈药 | 哈药集团有限公司 | | 43 | 北大分 | 黑龙江北大众集团有限公司 | | 序号 | 品牌 ...

证券日报网讯12月22日，九芝堂（000989）在互动平台回答投资者提问时表示，公司关注AI技术在公 司业务领域内的发展及应用。 ...

Group 1 - The company disclosed that the net profit attributable to shareholders for the year-to-date period up to the end of the reporting period in the third quarter of 2025 is 151,531,605.68 yuan [2]

Core Viewpoint - The company Ji Xiang Long is leveraging downstream formulation demand to boost sales of upstream raw materials and chemicals, benefiting from the market opportunities created by the expansion of medical insurance coverage [1] Domestic Market - Ji Xiang Long is driving sales of raw materials and chemicals by relying on the demand from the downstream formulation sector [1] - The company is enjoying market dividends from the expansion of medical insurance in the domestic market [1] International Market - Ji Xiang Long primarily exports GLP-1 class drugs (Semaglutide, Tirzepatide) and has obtained DMF registration [1] - The company has not yet received FDA certification as it has not applied for formulation-related approval, thus it is currently exporting in the form of chemicals [1]

Group 1 - The company has approved an external investment plan to acquire a 51.6667% stake in Harbin Jixianglong Biotechnology Co., Ltd. (Jixianglong) through a total investment of RMB 31 million [2][3] - The investment includes RMB 21 million for acquiring existing shares and RMB 10 million for subscribing to new registered capital, resulting in a total registered capital of RMB 1,135.55 million for Jixianglong [2] - Following the completion of the transaction, Jixianglong will become a subsidiary of the company and will be included in the consolidated financial statements [2][3] Group 2 - The company has successfully completed the necessary business registration changes and obtained the business license from the Harbin New Area Management Committee [3]

公告文件 证券代码：000989 证券简称： 九芝堂 公告编号：2025-075 九芝堂股份有限公司 九芝堂股份有限公司董事会 一、对外投资的基本情况 九芝堂股份有限公司（以下简称"公司"）第九届董事会第十一次会议审议通 过了《关于对外投资的议案》并签署相关协议，公司以人民币 21,000 万元受让 哈尔滨吉象隆生物技术有限公司（以下简称"吉象隆"）原股东冷国庆、哈尔滨 创新创业投资有限公司、东晶、张琪、李晨阳、肖明辉、朱德宝、郭健合计持有 的吉象隆已实缴注册资本 769.2435 万元（对应本次交易完成后 35%的标的公司 股权），并以人民币 10,000 万元认购吉象隆 366.3065 万元的新增注册资本（对应 本次交易完成后 16.6667%的标的公司股权）。前述交易方案完成后，公司将持有 吉象隆 51.6667%的股权，对应吉象隆 1,135.5500 万元注册资本。吉象隆将成为 公司的控股子公司，纳入公司合并报表范围。 具体内容详见公司于 2025 年 10 月 30 日披露的《九芝堂股份有限公司关于 对外投资的公告》（2025-069）。 二、对外投资的进展情况 吉象隆已于近日完成股权转让及增加 ...

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Group 1 - The company has received a notification from a shareholder, Li Zhengguo, regarding the pledge of part of his shares, which does not involve significant asset restructuring or performance compensation obligations [1] - As of November 26, 2025, the pledged shares held by the shareholder are detailed, including those resulting from his position as vice chairman and general manager, which are subject to lock-up [2] - The company will continue to monitor the situation and fulfill its information disclosure obligations in accordance with relevant laws and regulations [3] Group 2 - The company has provided a list of documents for reference, including the securities pledge and judicial freeze details from the China Securities Depository and Clearing Corporation [4] - The board of directors of the company issued this notification on November 28, 2025 [5]

Core Points - The company, JiuZhiTang, announced that it received a notification from its major shareholder, Li Zhenguo, regarding the pledge of part of his shares [2] - The pledged amount is 13,160,000 shares [2]

Group 1 - The core point of the article is that Jiuzhitang (SZ 000989) announced a significant share pledge by its major shareholder, Li Zhenguo, who has pledged 13.16 million shares, bringing the total pledged shares to 93.63 million, which is 57.83% of his holdings [1] - As of the announcement date, Jiuzhitang's market capitalization is 8 billion yuan [1] - The revenue composition for Jiuzhitang for the first half of 2025 shows that the pharmaceutical industry accounts for 97.17%, pharmaceutical commerce for 2.63%, and other businesses for 0.2% [1]